HRP20040501A2 - Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellirus - Google Patents

Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellirus

Info

Publication number: HRP20040501A2
Authority: HR; Croatia
Prior art keywords: glibenclamide; metformin; layer; tablets; pharmaceutical formulations
Prior art date: 2001-11-29

Application number

Other languages

English (en)

Croatian (hr)

Inventor

Alessandro Tosetti

Mauro Guiducci

Giovanni Viti

Original Assignee

Menarini Int Operations Lu Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-29

Filing date

2004-06-04

Publication date

2004-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11442301&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040501(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-04 Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa

2004-12-31 Publication of HRP20040501A2 publication Critical patent/HRP20040501A2/hr

Links

ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 title claims description 135
229960004580 glibenclamide Drugs 0.000 title claims description 131
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims description 127
239000008194 pharmaceutical composition Substances 0.000 title claims description 22
208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 10
238000011282 treatment Methods 0.000 title claims description 9
239000003826 tablet Substances 0.000 claims description 125
229960003105 metformin Drugs 0.000 claims description 107
239000000203 mixture Substances 0.000 claims description 64
238000002360 preparation method Methods 0.000 claims description 43
239000000546 pharmaceutical excipient Substances 0.000 claims description 26
239000004480 active ingredient Substances 0.000 claims description 21
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
239000008119 colloidal silica Substances 0.000 claims description 18
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 16
238000009472 formulation Methods 0.000 claims description 13
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 12
239000004094 surface-active agent Substances 0.000 claims description 12
239000002270 dispersing agent Substances 0.000 claims description 11
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 9
229920002785 Croscarmellose sodium Polymers 0.000 claims description 9
229960001021 lactose monohydrate Drugs 0.000 claims description 9
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
229910002027 silica gel Inorganic materials 0.000 claims description 8
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 7
229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
239000008108 microcrystalline cellulose Substances 0.000 claims description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
229940043264 dodecyl sulfate Drugs 0.000 claims description 6
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 6
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
239000013543 active substance Substances 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
229960005168 croscarmellose Drugs 0.000 claims description 4
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
239000007942 layered tablet Substances 0.000 claims description 3
229960003511 macrogol Drugs 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Chemical class 0.000 claims description 3
229940068968 polysorbate 80 Drugs 0.000 claims description 3
229920000053 polysorbate 80 Chemical class 0.000 claims description 3
239000003513 alkali Substances 0.000 claims description 2
-1 alkaline earth metal salts Chemical class 0.000 claims description 2
239000011248 coating agent Substances 0.000 claims description 2
238000000576 coating method Methods 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 22
235000019359 magnesium stearate Nutrition 0.000 claims 11
239000004407 iron oxides and hydroxides Substances 0.000 claims 8
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims 8
229910002012 Aerosil® Inorganic materials 0.000 claims 6
239000011777 magnesium Substances 0.000 claims 6
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 5
229960001681 croscarmellose sodium Drugs 0.000 claims 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 5
229920003084 Avicel® PH-102 Polymers 0.000 claims 3
229920002261 Corn starch Polymers 0.000 claims 3
239000008120 corn starch Substances 0.000 claims 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims 2
229960001375 lactose Drugs 0.000 claims 2
239000008101 lactose Substances 0.000 claims 2
239000000454 talc Substances 0.000 claims 2
229910052623 talc Inorganic materials 0.000 claims 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
108010010803 Gelatin Proteins 0.000 claims 1
239000002202 Polyethylene glycol Substances 0.000 claims 1
239000000443 aerosol Substances 0.000 claims 1
229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
239000008273 gelatin Substances 0.000 claims 1
229920000159 gelatin Polymers 0.000 claims 1
235000019322 gelatine Nutrition 0.000 claims 1
235000011852 gelatine desserts Nutrition 0.000 claims 1
235000011187 glycerol Nutrition 0.000 claims 1
239000000377 silicon dioxide Substances 0.000 claims 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
238000005469 granulation Methods 0.000 description 9
230000003179 granulation Effects 0.000 description 9
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
238000000034 method Methods 0.000 description 8
230000008901 benefit Effects 0.000 description 7
239000008187 granular material Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
229940123208 Biguanide Drugs 0.000 description 6
102000004877 Insulin Human genes 0.000 description 6
108090001061 Insulin Proteins 0.000 description 6
229940100389 Sulfonylurea Drugs 0.000 description 6
150000004283 biguanides Chemical class 0.000 description 6
229940125396 insulin Drugs 0.000 description 6
229960004329 metformin hydrochloride Drugs 0.000 description 5
238000002156 mixing Methods 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003628 erosive effect Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 3
230000007423 decrease Effects 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000004040 coloring Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
238000009509 drug development Methods 0.000 description 2
229940095884 glucophage Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229940127017 oral antidiabetic Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
101100533387 Homo sapiens SCGB1D1 gene Proteins 0.000 description 1
102100028659 Secretoglobin family 1D member 1 Human genes 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001761 chlorpropamide Drugs 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000011812 mixed powder Substances 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HRP20040501 2001-11-29 2004-06-04 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellirus HRP20040501A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2001FI000230A ITFI20010230A1 (it)	2001-11-29	2001-11-29	Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
PCT/EP2002/013497 WO2003045355A1 (en)	2001-11-29	2002-11-29	Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus

Publications (1)

Publication Number	Publication Date
HRP20040501A2 true HRP20040501A2 (en)	2004-12-31

Family

ID=11442301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20040501 HRP20040501A2 (en)	2001-11-29	2004-06-04	Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellirus

Country Status (40)

Country	Link
US (1)	US20050053661A1 (el)
EP (1)	EP1458364B1 (el)
JP (1)	JP4474162B2 (el)
KR (1)	KR20040079898A (el)
CN (1)	CN1596103B (el)
AR (1)	AR037407A1 (el)
AT (1)	ATE387190T1 (el)
AU (1)	AU2002358061B2 (el)
BR (1)	BR0214403A (el)
CA (1)	CA2466677A1 (el)
CO (1)	CO5590906A2 (el)
CY (1)	CY1107966T1 (el)
DE (1)	DE60225331T2 (el)
DK (1)	DK1458364T3 (el)
EA (1)	EA006766B1 (el)
EG (1)	EG24124A (el)
ES (1)	ES2302862T3 (el)
HK (1)	HK1069974A1 (el)
HN (1)	HN2002000341A (el)
HR (1)	HRP20040501A2 (el)
HU (1)	HUP0402154A3 (el)
IL (1)	IL162143A0 (el)
IT (1)	ITFI20010230A1 (el)
MA (1)	MA27087A1 (el)
MX (1)	MXPA04004974A (el)
MY (1)	MY141243A (el)
NO (1)	NO20042713L (el)
NZ (1)	NZ533779A (el)
PA (1)	PA8559801A1 (el)
PE (1)	PE20030580A1 (el)
PL (1)	PL206016B1 (el)
PT (1)	PT1458364E (el)
RS (1)	RS50937B (el)
SI (1)	SI1458364T1 (el)
SV (1)	SV2004001415A (el)
TN (1)	TNSN04095A1 (el)
UA (1)	UA81615C2 (el)
UY (1)	UY27549A1 (el)
WO (1)	WO2003045355A1 (el)
ZA (1)	ZA200404880B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL362687A1 (en) *	2001-01-12	2004-11-02	Sun Pharmaceutical Industries Limited	Spaced drug delivery system
US8911781B2 (en)	2002-06-17	2014-12-16	Inventia Healthcare Private Limited	Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en)	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
DK2316456T3 (en)	2003-04-29	2017-09-11	Orexigen Therapeutics Inc	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
UY29445A1 (es) *	2005-03-30	2006-10-02	Generex Pharm Inc	Composiciones para la transmisión transmucosa oral de la metformina
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
KR101735466B1 (ko) *	2006-11-09	2017-05-15	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
ITMI20062254A1 (it) *	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
CA2638240C (en)	2008-08-29	2010-02-02	Alexander Macgregor	Method of treating dysglycemia and glucose excursions
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
RU2483717C2 (ru) *	2010-11-22	2013-06-10	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Фармацевтическая композиция для лечения диабета (варианты)
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2013103919A2 (en)	2012-01-06	2013-07-11	Elcelyx Therapeutics, Inc.	Compositions and methods for treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
KR20140035331A (ko)	2011-01-07	2014-03-21	엘셀릭스 테라퓨틱스 인코포레이티드	화학감각 수용체 리간드-기반 요법
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
KR102035879B1 (ko)	2012-01-06	2019-10-23	엘셀릭스 테라퓨틱스 인코포레이티드	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
LT3730132T (lt)	2012-06-06	2022-08-25	Nalpropion Pharmaceuticals Llc	Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
WO2016076280A1 (ja)	2014-11-11	2016-05-19	塩野義製薬株式会社	光に対して不安定な薬物を含有する多層錠剤
KR101750690B1 (ko) *	2015-10-28	2017-06-27	주식회사 종근당	메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
CN105596339A (zh) *	2015-12-23	2016-05-25	青岛海之源智能技术有限公司	一种二甲双胍阿昔莫司复方组合物及制备方法
CN110128305A (zh) *	2019-05-10	2019-08-16	天津大学	二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途
JP2021120357A (ja) *	2020-01-30	2021-08-19	サンノーバ株式会社	錠剤
GB2599950A (en) *	2020-10-16	2022-04-20	Zentiva Ks	Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
CN113143940A (zh) *	2020-12-30	2021-07-23	成都恒瑞制药有限公司	一种抗糖尿病药物组合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2347531A1 (de) *	1973-09-21	1975-04-30	Hoechst Ag	Arzneizubereitungen zur oralen diabetes-behandlung
IT1276130B1 (it) *	1995-11-14	1997-10-27	Gentili Ist Spa	Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
NZ506202A (en) *	1998-03-19	2003-10-31	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
DK0974356T3 (da) *	1998-07-15	2003-10-27	Merck Sante Sas	Tabletter omfattende en kombination af metformin og glibenclamid
US6780432B1 (en) *	2000-05-01	2004-08-24	Aeropharm Technology, Inc.	Core formulation
PL362687A1 (en) *	2001-01-12	2004-11-02	Sun Pharmaceutical Industries Limited	Spaced drug delivery system

2001
- 2001-11-29 IT IT2001FI000230A patent/ITFI20010230A1/it unknown
2002
- 2002-11-22 AR ARP020104498A patent/AR037407A1/es unknown
- 2002-11-25 MY MYPI20024393A patent/MY141243A/en unknown
- 2002-11-26 PE PE2002001140A patent/PE20030580A1/es not_active Application Discontinuation
- 2002-11-26 UY UY27549A patent/UY27549A1/es not_active Application Discontinuation
- 2002-11-27 EG EG2002111281A patent/EG24124A/xx active
- 2002-11-28 SV SV2002001415A patent/SV2004001415A/es not_active Application Discontinuation
- 2002-11-29 EA EA200400664A patent/EA006766B1/ru not_active IP Right Cessation
- 2002-11-29 DK DK02791739T patent/DK1458364T3/da active
- 2002-11-29 MX MXPA04004974A patent/MXPA04004974A/es active IP Right Grant
- 2002-11-29 DE DE60225331T patent/DE60225331T2/de not_active Expired - Lifetime
- 2002-11-29 SI SI200230693T patent/SI1458364T1/sl unknown
- 2002-11-29 UA UA20040504085A patent/UA81615C2/ru unknown
- 2002-11-29 HN HN2002000341A patent/HN2002000341A/es unknown
- 2002-11-29 CN CN028236920A patent/CN1596103B/zh not_active Expired - Fee Related
- 2002-11-29 WO PCT/EP2002/013497 patent/WO2003045355A1/en active IP Right Grant
- 2002-11-29 KR KR10-2004-7006874A patent/KR20040079898A/ko not_active Application Discontinuation
- 2002-11-29 PL PL369851A patent/PL206016B1/pl not_active IP Right Cessation
- 2002-11-29 BR BR0214403-4A patent/BR0214403A/pt not_active IP Right Cessation
- 2002-11-29 AU AU2002358061A patent/AU2002358061B2/en not_active Ceased
- 2002-11-29 PA PA20028559801A patent/PA8559801A1/es unknown
- 2002-11-29 PT PT02791739T patent/PT1458364E/pt unknown
- 2002-11-29 CA CA002466677A patent/CA2466677A1/en not_active Abandoned
- 2002-11-29 HU HU0402154A patent/HUP0402154A3/hu unknown
- 2002-11-29 JP JP2003546858A patent/JP4474162B2/ja not_active Expired - Lifetime
- 2002-11-29 NZ NZ533779A patent/NZ533779A/en not_active IP Right Cessation
- 2002-11-29 AT AT02791739T patent/ATE387190T1/de not_active IP Right Cessation
- 2002-11-29 IL IL16214302A patent/IL162143A0/xx not_active IP Right Cessation
- 2002-11-29 US US10/497,022 patent/US20050053661A1/en not_active Abandoned
- 2002-11-29 EP EP02791739A patent/EP1458364B1/en not_active Expired - Lifetime
- 2002-11-29 ES ES02791739T patent/ES2302862T3/es not_active Expired - Lifetime
2004
- 2004-05-24 MA MA27696A patent/MA27087A1/fr unknown
- 2004-05-28 TN TNP2004000095A patent/TNSN04095A1/en unknown
- 2004-05-28 RS YUP-473/04A patent/RS50937B/sr unknown
- 2004-06-04 HR HRP20040501 patent/HRP20040501A2/hr not_active Application Discontinuation
- 2004-06-21 ZA ZA200404880A patent/ZA200404880B/en unknown
- 2004-06-28 NO NO20042713A patent/NO20042713L/no not_active Application Discontinuation
- 2004-06-29 CO CO04061363A patent/CO5590906A2/es not_active Application Discontinuation
2005
- 2005-03-18 HK HK05102373A patent/HK1069974A1/xx not_active IP Right Cessation
2008
- 2008-05-26 CY CY20081100543T patent/CY1107966T1/el unknown

Also Published As

Publication number	Publication date
HUP0402154A3 (en)	2008-04-28
MY141243A (en)	2010-03-31
WO2003045355A1 (en)	2003-06-05
HUP0402154A2 (hu)	2005-02-28
PL206016B1 (pl)	2010-06-30
MA27087A1 (fr)	2004-12-20
ATE387190T1 (de)	2008-03-15
RS47304A (en)	2006-10-27
JP4474162B2 (ja)	2010-06-02
MXPA04004974A (es)	2004-08-11
HK1069974A1 (en)	2005-06-10
AR037407A1 (es)	2004-11-10
RS50937B (sr)	2010-08-31
SI1458364T1 (sl)	2008-08-31
PT1458364E (pt)	2008-05-26
JP2005518360A (ja)	2005-06-23
PE20030580A1 (es)	2003-09-05
PA8559801A1 (es)	2003-06-30
CY1107966T1 (el)	2013-09-04
ES2302862T3 (es)	2008-08-01
CO5590906A2 (es)	2005-12-30
EG24124A (en)	2008-07-07
AU2002358061A1 (en)	2003-06-10
CN1596103B (zh)	2010-06-16
DE60225331D1 (de)	2008-04-10
EA006766B1 (ru)	2006-04-28
AU2002358061B2 (en)	2007-01-11
DE60225331T2 (de)	2009-02-26
CA2466677A1 (en)	2003-06-05
NZ533779A (en)	2007-02-23
US20050053661A1 (en)	2005-03-10
IL162143A0 (en)	2005-11-20
DK1458364T3 (da)	2008-06-23
UY27549A1 (es)	2003-06-30
TNSN04095A1 (en)	2006-06-01
KR20040079898A (ko)	2004-09-16
EP1458364A1 (en)	2004-09-22
NO20042713L (no)	2004-07-16
EP1458364B1 (en)	2008-02-27
CN1596103A (zh)	2005-03-16
EA200400664A1 (ru)	2004-10-28
PL369851A1 (en)	2005-05-02
ITFI20010230A1 (it)	2003-05-29
ZA200404880B (en)	2005-07-29
HN2002000341A (es)	2009-12-07
SV2004001415A (es)	2004-05-07
UA81615C2 (ru)	2008-01-25
BR0214403A (pt)	2004-10-19

Publication	Publication Date	Title
HRP20040501A2 (en)	2004-12-31	Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellirus
AU753604B2 (en)	2002-10-24	Solid oral dosage form comprising a combination of metformin and glibenclamide
JP4633329B2 (ja)	2011-02-16	スペーストドラッグデリバリーシステム
TWI280125B (en)	2007-05-01	Pharmaceutical compositions for treating type 2 diabetes in drug naive human patients
US20060057202A1 (en)	2006-03-16	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP2590631B1 (en)	2016-10-26	Formulation for co-therapy treatment of diabetes
JP2012530135A (ja)	2012-11-29	ジペプチジルペプチダーゼ−４阻害剤及びピオグリタゾンの併用医薬組成物
CN104220049A (zh)	2014-12-17	包含二甲双胍和dpp-4抑制剂或sglt-2抑制剂的药物组合物
NZ552074A (en)	2008-06-30	Antidiabetic combination of metformin and one other antidiabetic agent such as a sulfonyl urea
MXPA05009633A (es)	2007-03-07	Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
CN101780095A (zh)	2010-07-21	抗糖尿病的药物制剂及方法
WO2004045608A1 (en)	2004-06-03	Pharmaceutical compositions containing a biguanide-glitazone combination
CN101155586A (zh)	2008-04-02	包含罗格列酮的口服剂型
JP2002326927A (ja)	2002-11-15	塩酸メトホルミン含有速放性錠剤
US20040147564A1 (en)	2004-07-29	Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CN102397551A (zh)	2012-04-04	包括罗格列酮和另一种抗糖尿病药的新组合物
AU2004290505B2 (en)	2007-09-20	Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic.
CN101919851B (zh)	2012-02-08	治疗哺乳动物包括人2型糖尿病的药物组合物
WO2004069229A1 (en)	2004-08-19	Dual release anti-diabetic drugs and process of production thereof
WO2017115252A1 (en)	2017-07-06	An oral osmotic pharmaceutical composition of vildagliptin
CN101961336A (zh)	2011-02-02	治疗哺乳动物包括人2型糖尿病的药物组合物
WO2004091587A1 (en)	2004-10-28	Multiple release anti-diabetic drugs and process of production thereof
JP2007535557A (ja)	2007-12-06	制御放出メトフォルミン組成物

Legal Events

Date	Code	Title	Description
2004-12-31	A1OB	Publication of a patent application
2005-06-29	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2009-11-19	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20091119 Year of fee payment: 8
2011-06-07	OBST	Application withdrawn